US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

12.72

+0.80006.71%

Post-market: 12.750.0300+0.24%19:55 EDT

Volume:1.19M

Turnover:14.82M

Market Cap:905.54M

PE:-14.68

High:12.75

Open:12.24

Low:12.07

Close:11.92

52wk High:15.10

52wk Low:1.94

Shares:71.19M

Float Shares:58.79M

Volume Ratio:0.93

T/O Rate:2.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8667

EPS(LYR):-0.8930

ROE:-34.18%

ROA:-20.52%

PB:3.96

PE(LYR):-14.24

Loading ...

Overview Company News Filings

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From Relapsed/Refractory Al Amyloidosis Clinical Trial Nexicart-2

THOMSON REUTERS

Immix Biopharma, Inc: Next Nexicart-2 Update Expected Late September, 2026

THOMSON REUTERS

Immix Biopharma Inc - Plans to Initiate Phase 3 Trial in Newly Diagnosed Al Amyloidosis Patients

THOMSON REUTERS

Immix Biopharma: by March End 2027, Expect to Present 1-Year Follow-up Data of Enrolled Patients; Sees It to Drive Bla Submission, Commercial Launch

THOMSON REUTERS

Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Simply Wall St.

Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis

Immix Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Immix Biopharma Q1 net loss widens to USD 10.09 million

Immix Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis

Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis

Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings

Immix Biopharma announces annual shareholder meeting

Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates

THOMSON REUTERS

Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon

Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial

Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones

THOMSON REUTERS

Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/IMMX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":12.72,"timestamp":1789675200000,"preClose":11.92,"halted":0,"volume":1185668,"hourTrading":{"tag":"盘后","latestPrice":12.75,"preClose":12.72,"latestTime":"19:55 EDT","volume":10471,"amount":133253.0872,"timestamp":1789689359653,"change":0.03,"changeRate":0.002358,"amplitude":0.003042},"delay":0,"changeRate":0.0671140939597316,"floatShares":58787133,"shares":71190000,"eps":-0.8667,"marketStatus":"Not Yet Opened","change":0.8,"latestTime":"09-17 16:00:00 EDT","open":12.24,"high":12.75,"low":12.07,"amount":14823150.19592,"amplitude":0.057047,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.8667,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":0,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":11.92,"preHourTrading":{"tag":"盘前","latestPrice":12.2,"preClose":11.92,"latestTime":"09:25 EDT","volume":9093,"amount":110419.581573,"timestamp":1789651553747,"change":0.28,"changeRate":0.02349,"amplitude":0.107383},"postHourTrading":{"tag":"盘后","latestPrice":12.75,"preClose":12.72,"latestTime":"19:55 EDT","volume":10471,"amount":133253.0872,"timestamp":1789689359653,"change":0.03,"changeRate":0.002358,"amplitude":0.003042},"volumeRatio":0.925805,"impliedVol":1.6648,"impliedVolPercentile":0.8327},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","floatShares":58787133,"roa":"-20.52%","roe":"-34.18%","lyrEps":-0.893007,"volumeRatio":0.925805,"shares":71190000,"dividePrice":0,"high":12.75,"amplitude":0.057047,"preClose":11.92,"low":12.07,"week52Low":1.94,"pbRate":"3.96","week52High":15.1,"institutionHeld":0,"latestPrice":12.72,"eps":-0.8667,"divideRate":0,"volume":1185668,"delay":0,"ttmEps":-0.8667,"open":12.24,"prevYearClose":5.23,"prevWeekClose":12.14,"prevMonthClose":14.03,"prevQuarterClose":10.31,"fiveDayClose":12.7,"twentyDayClose":13.19,"sixtyDayClose":9.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"IMMX","fiscalQuarterEnding":"2026/06","expectedEps":-0.17,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2026-05-07","symbol":"IMMX","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2026-03-25","symbol":"IMMX","fiscalQuarterEnding":"2025/12","expectedEps":-0.16,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-11-07","symbol":"IMMX","fiscalQuarterEnding":"2025/09","expectedEps":-0.19,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2025-08-08","symbol":"IMMX","fiscalQuarterEnding":"2025/06","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1429,"buy":0.8571,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8571,"analysts":7,"updateTime":1784779200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMMX","date":"2026-09-16","current":-14.676359,"percent":0.048027,"low":-37.240428,"twenty":-11.593976,"median":-3.189215,"eighty":-1.479611,"high":-0.384227,"avg":-6.458569,"sd":7.038361,"marketCap":868487271},"quantilePoints":[{"date":"2021-12-17","current":-22.068402,"twenty":-20.976016,"median":-17.642249,"eighty":-15.03674,"marketCap":52834756},{"date":"2021-12-23","current":-16.275446,"twenty":-19.828459,"median":-17.958163,"eighty":-15.532222,"marketCap":38965632},{"date":"2021-12-31","current":-19.640878,"twenty":-19.806391,"median":-18.096089,"eighty":-16.937498,"marketCap":47022932},{"date":"2022-01-07","current":-29.461317,"twenty":-29.957856,"median":-19.420194,"eighty":-17.952645,"marketCap":70534399},{"date":"2022-01-14","current":-32.219867,"twenty":-32.197799,"median":-20.247759,"eighty":-17.985748,"marketCap":77138743},{"date":"2022-01-21","current":-24.882123,"twenty":-32.142628,"median":-24.882123,"eighty":-18.007816,"marketCap":59571187},{"date":"2022-01-28","current":-21.461521,"twenty":-32.021251,"median":-22.399428,"eighty":-18.140226,"marketCap":51381800},{"date":"2022-02-04","current":-24.109729,"twenty":-31.756431,"median":-22.399428,"eighty":-18.493321,"marketCap":57721970},{"date":"2022-02-11","current":-23.282164,"twenty":-31.039208,"median":-23.30975,"eighty":-19.276749,"marketCap":55740667},{"date":"2022-02-18","current":-19.75122,"twenty":-30.222677,"median":-22.399428,"eighty":-19.59674,"marketCap":47287106},{"date":"2022-02-25","current":-17.654721,"twenty":-29.957856,"median":-22.123573,"eighty":-18.096089,"marketCap":42267804},{"date":"2022-03-04","current":-11.641082,"twenty":-29.902685,"median":-21.875304,"eighty":-17.875406,"marketCap":27870333},{"date":"2022-03-11","current":-10.261807,"twenty":-29.461317,"median":-21.461521,"eighty":-16.440959,"marketCap":24568161},{"date":"2022-03-18","current":-13.296212,"twenty":-27.199305,"median":-20.771884,"eighty":-15.03674,"marketCap":31832940},{"date":"2022-03-25","current":-11.751424,"twenty":-26.592424,"median":-19.75122,"eighty":-13.241041,"marketCap":28134507},{"date":"2022-04-01","current":-1.409519,"twenty":-26.482082,"median":-19.392608,"eighty":-11.751424,"marketCap":34369548},{"date":"2022-04-08","current":-1.028722,"twenty":-25.433833,"median":-18.096089,"eighty":-11.254885,"marketCap":25084227},{"date":"2022-04-14","current":-1.023038,"twenty":-24.992465,"median":-17.985748,"eighty":-10.416286,"marketCap":24945640},{"date":"2022-04-22","current":-0.818431,"twenty":-24.264208,"median":-17.765064,"eighty":-1.459534,"marketCap":19956512},{"date":"2022-04-29","current":-0.785819,"twenty":-24.109729,"median":-17.047841,"eighty":-1.310625,"marketCap":19161305},{"date":"2022-05-06","current":-0.848456,"twenty":-23.491814,"median":-15.778907,"eighty":-1.093514,"marketCap":20688655},{"date":"2022-05-13","current":-0.733622,"twenty":-23.293198,"median":-15.03674,"eighty":-0.9878,"marketCap":18119930},{"date":"2022-05-20","current":-1.191784,"twenty":-22.840796,"median":-13.351383,"eighty":-0.962793,"marketCap":29436208},{"date":"2022-05-27","current":-1.506595,"twenty":-22.465633,"median":-12.854844,"eighty":-0.975297,"marketCap":37211810},{"date":"2022-06-03","current":-1.394163,"twenty":-22.30012,"median":-12.247963,"eighty":-0.98098,"marketCap":34434809},{"date":"2022-06-10","current":-1.366055,"twenty":-22.16771,"median":-11.696253,"eighty":-0.986663,"marketCap":33740559},{"date":"2022-06-17","current":-1.366055,"twenty":-22.09047,"median":-11.254885,"eighty":-1.009398,"marketCap":33740559},{"date":"2022-06-24","current":-1.197406,"twenty":-22.046334,"median":-10.482491,"eighty":-1.025312,"marketCap":29575058},{"date":"2022-07-01","current":-1.461622,"twenty":-21.902889,"median":-10.344563,"eighty":-1.033234,"marketCap":36101010},{"date":"2022-07-08","current":-1.506595,"twenty":-21.737376,"median":-5.965715,"eighty":-1.047976,"marketCap":37211810},{"date":"2022-07-15","current":-1.534704,"twenty":-21.682205,"median":-1.669623,"eighty":-1.083284,"marketCap":37906060},{"date":"2022-07-22","current":-1.377298,"twenty":-21.461521,"median":-1.540325,"eighty":-1.107154,"marketCap":34018259},{"date":"2022-07-29","current":-1.371676,"twenty":-21.428418,"median":-1.529082,"eighty":-1.149213,"marketCap":33879409},{"date":"2022-08-05","current":-1.414851,"twenty":-21.086358,"median":-1.509406,"eighty":-1.161365,"marketCap":34945778},{"date":"2022-08-12","current":-1.308074,"twenty":-20.181554,"median":-1.484109,"eighty":-1.191784,"marketCap":34079789},{"date":"2022-08-19","current":-1.073155,"twenty":-19.88363,"median":-1.475262,"eighty":-1.182306,"marketCap":27959337},{"date":"2022-08-26","current":-1.09985,"twenty":-19.729152,"median":-1.461622,"eighty":-1.149213,"marketCap":28654843},{"date":"2022-09-02","current":-1.035781,"twenty":-19.629844,"median":-1.425082,"eighty":-1.094994,"marketCap":26985628},{"date":"2022-09-09","current":-0.961034,"twenty":-19.585706,"median":-1.416649,"eighty":-1.051798,"marketCap":25038212},{"date":"2022-09-16","current":-0.977051,"twenty":-19.19951,"median":-1.413839,"eighty":-1.023038,"marketCap":25455515},{"date":"2022-09-23","current":-0.787514,"twenty":-18.316774,"median":-1.407462,"eighty":-0.983253,"marketCap":20517424},{"date":"2022-09-30","current":-0.726114,"twenty":-18.096089,"median":-1.388541,"eighty":-0.966203,"marketCap":18917760},{"date":"2022-10-07","current":-0.69408,"twenty":-17.985748,"median":-1.380109,"eighty":-0.928999,"marketCap":18083153},{"date":"2022-10-14","current":-0.646028,"twenty":-17.985748,"median":-1.371676,"eighty":-0.916325,"marketCap":16831242},{"date":"2022-10-21","current":-0.630011,"twenty":-17.930577,"median":-1.366055,"eighty":-0.871234,"marketCap":16413939},{"date":"2022-10-28","current":-0.573951,"twenty":-17.875406,"median":-1.366055,"eighty":-0.854252,"marketCap":14953376},{"date":"2022-11-04","current":-0.485856,"twenty":-17.654721,"median":-1.352001,"eighty":-0.819985,"marketCap":12658207},{"date":"2022-11-11","current":-0.448265,"twenty":-17.213353,"median":-1.343568,"eighty":-0.800862,"marketCap":12186169},{"date":"2022-11-18","current":-0.665994,"twenty":-17.047841,"median":-1.333979,"eighty":-0.785819,"marketCap":18105187},{"date":"2022-11-25","current":-0.686486,"twenty":-16.562335,"median":-1.321082,"eighty":-0.77203,"marketCap":18662269},{"date":"2022-12-02","current":-0.588739,"twenty":-16.308549,"median":-1.309839,"eighty":-0.750858,"marketCap":16004985},{"date":"2022-12-09","current":-0.712102,"twenty":-15.480984,"median":-1.267676,"eighty":-0.736159,"marketCap":19358623},{"date":"2022-12-16","current":-0.968253,"twenty":-15.085866,"median":-1.244005,"eighty":-0.741064,"marketCap":26322156},{"date":"2022-12-23","current":-1.111698,"twenty":-15.03674,"median":-1.214271,"eighty":-0.746567,"marketCap":30221735},{"date":"2022-12-30","current":-1.173175,"twenty":-14.853091,"median":-1.211283,"eighty":-0.747676,"marketCap":31892983},{"date":"2023-01-06","current":-1.19879,"twenty":-14.201016,"median":-1.209622,"eighty":-0.747791,"marketCap":32589336},{"date":"2023-01-13","current":-1.127067,"twenty":-13.362417,"median":-1.203028,"eighty":-0.749439,"marketCap":30639547},{"date":"2023-01-20","current":-1.101452,"twenty":-13.285178,"median":-1.197406,"eighty":-0.751884,"marketCap":29943194},{"date":"2023-01-27","current":-1.229528,"twenty":-13.163802,"median":-1.200909,"eighty":-0.753717,"marketCap":33424960},{"date":"2023-02-03","current":-1.608632,"twenty":-12.744502,"median":-1.208649,"eighty":-0.758575,"marketCap":43730990},{"date":"2023-02-10","current":-1.357604,"twenty":-12.2921,"median":-1.211283,"eighty":-0.764481,"marketCap":36906727},{"date":"2023-02-17","current":-1.173175,"twenty":-12.148655,"median":-1.210595,"eighty":-0.769597,"marketCap":31892983},{"date":"2023-02-24","current":-1.101452,"twenty":-11.751424,"median":-1.203913,"eighty":-0.774166,"marketCap":29943194},{"date":"2023-03-03","current":-1.075837,"twenty":-11.751424,"median":-1.198098,"eighty":-0.77443,"marketCap":29246840},{"date":"2023-03-10","current":-0.922146,"twenty":-11.641082,"median":-1.191784,"eighty":-0.785819,"marketCap":25068720},{"date":"2023-03-17","current":-0.932392,"twenty":-11.365227,"median":-1.185983,"eighty":-0.785819,"marketCap":25347261},{"date":"2023-03-24","current":-0.935614,"twenty":-11.254885,"median":-1.179936,"eighty":-0.787514,"marketCap":25434844},{"date":"2023-03-31","current":-3.073723,"twenty":-10.915583,"median":-1.185983,"eighty":-0.791513,"marketCap":25295856},{"date":"2023-04-06","current":-2.938614,"twenty":-10.569109,"median":-1.191784,"eighty":-0.796068,"marketCap":24183950},{"date":"2023-04-14","current":-2.98928,"twenty":-10.438354,"median":-1.197406,"eighty":-0.800131,"marketCap":24600914},{"date":"2023-04-21","current":-3.175054,"twenty":-10.383183,"median":-1.20347,"eighty":-0.807049,"marketCap":26129785},{"date":"2023-04-28","current":-3.884375,"twenty":-10.328012,"median":-1.210595,"eighty":-0.808596,"marketCap":31967290},{"date":"2023-05-05","current":-4.576322,"twenty":-10.272841,"median":-1.214215,"eighty":-0.816464,"marketCap":37661819},{"date":"2023-05-11","current":-3.813602,"twenty":-7.053908,"median":-1.216776,"eighty":-0.819363,"marketCap":31384849},{"date":"2023-05-19","current":-2.841134,"twenty":-4.874631,"median":-1.234651,"eighty":-0.836103,"marketCap":26642250},{"date":"2023-05-26","current":-2.380008,"twenty":-4.766155,"median":-1.244451,"eighty":-0.847813,"marketCap":22318115},{"date":"2023-06-02","current":-3.190234,"twenty":-4.657679,"median":-1.251483,"eighty":-0.848456,"marketCap":29915874},{"date":"2023-06-09","current":-3.254359,"twenty":-4.562763,"median":-1.270512,"eighty":-0.850774,"marketCap":30517199},{"date":"2023-06-16","current":-3.783393,"twenty":-4.400049,"median":-1.307224,"eighty":-0.856388,"marketCap":35478123},{"date":"2023-06-23","current":-4.10402,"twenty":-4.223113,"median":-1.309839,"eighty":-0.860781,"marketCap":38484743},{"date":"2023-06-30","current":-4.376552,"twenty":-4.23227,"median":-1.321082,"eighty":-0.865539,"marketCap":41040371},{"date":"2023-07-07","current":-4.152114,"twenty":-4.486677,"median":-1.332157,"eighty":-0.869324,"marketCap":38935736},{"date":"2023-07-14","current":-3.735299,"twenty":-4.39579,"median":-1.337947,"eighty":-0.871041,"marketCap":35027129},{"date":"2023-07-21","current":-3.572376,"twenty":-4.261126,"median":-1.345284,"eighty":-0.89609,"marketCap":33499345},{"date":"2023-07-28","current":-3.503009,"twenty":-4.195644,"median":-1.34919,"eighty":-0.905882,"marketCap":32848872},{"date":"2023-08-04","current":-3.503009,"twenty":-4.184638,"median":-1.356208,"eighty":-0.90747,"marketCap":32848872},{"date":"2023-08-11","current":-3.29491,"twenty":-4.158526,"median":-1.366055,"eighty":-0.911914,"marketCap":30897454},{"date":"2023-08-18","current":-2.330617,"twenty":-4.113639,"median":-1.367895,"eighty":-0.915656,"marketCap":26547513},{"date":"2023-08-25","current":-2.916846,"twenty":-4.034399,"median":-1.377298,"eighty":-0.920982,"marketCap":33225108},{"date":"2023-09-01","current":-2.902547,"twenty":-3.980385,"median":-1.38292,"eighty":-0.922146,"marketCap":33062240},{"date":"2023-09-08","current":-3.560267,"twenty":-3.968181,"median":-1.391352,"eighty":-0.923054,"marketCap":40554176},{"date":"2023-09-15","current":-3.631759,"twenty":-3.972707,"median":-1.409519,"eighty":-0.92366,"marketCap":41368517},{"date":"2023-09-22","current":-4.932901,"twenty":-4.034479,"median":-1.414345,"eighty":-0.926863,"marketCap":56189522},{"date":"2023-09-29","current":-6.358344,"twenty":-4.1851,"median":-1.416649,"eighty":-0.928999,"marketCap":72426414},{"date":"2023-10-06","current":-6.479291,"twenty":-4.315729,"median":-1.429506,"eighty":-0.931035,"marketCap":73804091},{"date":"2023-10-13","current":-5.615385,"twenty":-4.616006,"median":-1.461622,"eighty":-0.934325,"marketCap":63963545},{"date":"2023-10-20","current":-4.872427,"twenty":-4.777335,"median":-1.471175,"eighty":-0.943737,"marketCap":55500676},{"date":"2023-10-27","current":-6.375622,"twenty":-4.847512,"median":-1.475262,"eighty":-0.949152,"marketCap":72623225},{"date":"2023-11-03","current":-6.064616,"twenty":-4.932901,"median":-1.484109,"eighty":-0.950356,"marketCap":69080629},{"date":"2023-11-10","current":-6.410178,"twenty":-5.131598,"median":-1.509406,"eighty":-0.958007,"marketCap":73016847},{"date":"2023-11-17","current":-6.195423,"twenty":-5.719054,"median":-1.529082,"eighty":-0.961034,"marketCap":87580854},{"date":"2023-11-24","current":-6.703742,"twenty":-5.892712,"median":-1.540325,"eighty":-0.965169,"marketCap":94766658},{"date":"2023-12-01","current":-7.181577,"twenty":-6.076855,"median":-1.603509,"eighty":-0.967843,"marketCap":101521514},{"date":"2023-12-08","current":-7.01293,"twenty":-6.195898,"median":-1.669623,"eighty":-0.968253,"marketCap":99137447},{"date":"2023-12-15","current":-7.982654,"twenty":-6.218411,"median":-2.022607,"eighty":-0.97102,"marketCap":112845832},{"date":"2023-12-22","current":-10.034533,"twenty":-6.379078,"median":-2.409758,"eighty":-0.973043,"marketCap":141851979},{"date":"2023-12-29","current":-9.430212,"twenty":-6.451646,"median":-2.432071,"eighty":-0.974846,"marketCap":133309073},{"date":"2024-01-05","current":-8.50265,"twenty":-6.565681,"median":-2.473599,"eighty":-0.977051,"marketCap":120196705},{"date":"2024-01-12","current":-8.685352,"twenty":-6.703742,"median":-2.585988,"eighty":-0.97757,"marketCap":122779444},{"date":"2024-01-19","current":-7.518873,"twenty":-6.911741,"median":-2.60785,"eighty":-0.978313,"marketCap":106289648},{"date":"2024-01-26","current":-5.256184,"twenty":-7.018552,"median":-2.655395,"eighty":-0.982302,"marketCap":74303417},{"date":"2024-02-02","current":-5.466993,"twenty":-6.911741,"median":-2.795833,"eighty":-0.986834,"marketCap":77283501},{"date":"2024-02-09","current":-5.804128,"twenty":-6.774012,"median":-2.816758,"eighty":-0.987729,"marketCap":82049361},{"date":"2024-02-16","current":-5.229106,"twenty":-6.712174,"median":-2.843244,"eighty":-0.988695,"marketCap":73920631},{"date":"2024-02-23","current":-5.498647,"twenty":-6.703742,"median":-2.873951,"eighty":-0.994969,"marketCap":77730973},{"date":"2024-03-01","current":-6.019761,"twenty":-6.693474,"median":-2.904837,"eighty":-1.003911,"marketCap":85097634},{"date":"2024-03-08","current":-6.073669,"twenty":-6.663866,"median":-2.910842,"eighty":-1.008419,"marketCap":85859703},{"date":"2024-03-15","current":-5.10332,"twenty":-6.640353,"median":-2.938614,"eighty":-1.009238,"marketCap":72142472},{"date":"2024-03-22","current":-5.462708,"twenty":-6.634794,"median":-2.972392,"eighty":-1.015386,"marketCap":77222928},{"date":"2024-03-28","current":-5.516617,"twenty":-6.623022,"median":-3.014613,"eighty":-1.020906,"marketCap":77984996},{"date":"2024-04-05","current":-4.808357,"twenty":-6.594122,"median":-3.042817,"eighty":-1.023666,"marketCap":74173940},{"date":"2024-04-12","current":-4.945249,"twenty":-6.572627,"median":-3.073723,"eighty":-1.026253,"marketCap":76285653},{"date":"2024-04-19","current":-3.781661,"twenty":-6.536582,"median":-3.124388,"eighty":-1.031174,"marketCap":58336088},{"date":"2024-04-26","current":-3.593434,"twenty":-6.487476,"median":-3.158168,"eighty":-1.035224,"marketCap":55432482},{"date":"2024-05-03","current":-3.953922,"twenty":-6.475173,"median":-3.175054,"eighty":-1.037469,"marketCap":60993385},{"date":"2024-05-10","current":-3.731407,"twenty":-6.445469,"median":-3.190234,"eighty":-1.04472,"marketCap":57560857},{"date":"2024-05-17","current":-3.263275,"twenty":-6.403267,"median":-3.190234,"eighty":-1.053237,"marketCap":59409141},{"date":"2024-05-24","current":-3.07473,"twenty":-6.385989,"median":-3.190496,"eighty":-1.057425,"marketCap":55976613},{"date":"2024-05-31","current":-3.03122,"twenty":-6.372166,"median":-3.190496,"eighty":-1.060468,"marketCap":55184491},{"date":"2024-06-07","current":-2.988868,"twenty":-6.351433,"median":-3.175054,"eighty":-1.060468,"marketCap":54413458},{"date":"2024-06-14","current":-3.017886,"twenty":-6.323788,"median":-3.168385,"eighty":-1.060468,"marketCap":54941744},{"date":"2024-06-21","current":-2.785741,"twenty":-6.296199,"median":-3.161751,"eighty":-1.064566,"marketCap":50715456},{"date":"2024-06-28","current":-3.090431,"twenty":-6.282377,"median":-3.158171,"eighty":-1.065591,"marketCap":56262459},{"date":"2024-07-05","current":-3.554721,"twenty":-6.254675,"median":-3.158171,"eighty":-1.065591,"marketCap":64715035},{"date":"2024-07-12","current":-2.916322,"twenty":-6.209345,"median":-3.158168,"eighty":-1.070714,"marketCap":53092743},{"date":"2024-07-15","current":-3.061413,"twenty":-6.207036,"median":-3.158166,"eighty":-1.071202,"marketCap":55734173},{"date":"2024-08-02","current":-3.017886,"twenty":-6.204727,"median":-3.149722,"eighty":-1.07169,"marketCap":54941744},{"date":"2024-08-09","current":-2.901813,"twenty":-6.196849,"median":-3.133958,"eighty":-1.074228,"marketCap":52828600},{"date":"2024-08-16","current":-2.727429,"twenty":-6.184568,"median":-3.121919,"eighty":-1.075837,"marketCap":51881405},{"date":"2024-08-23","current":-3.189215,"twenty":-6.151983,"median":-3.124388,"eighty":-1.077452,"marketCap":60665558},{"date":"2024-08-30","current":-3.059338,"twenty":-6.126842,"median":-3.121919,"eighty":-1.082358,"marketCap":58195015},{"date":"2024-09-06","current":-3.030476,"twenty":-6.115383,"median":-3.11765,"eighty":-1.08762,"marketCap":57646005},{"date":"2024-09-13","current":-2.616311,"twenty":-6.073669,"median":-3.10494,"eighty":-1.093836,"marketCap":49767718},{"date":"2024-09-20","current":-2.554258,"twenty":-6.071858,"median":-3.096621,"eighty":-1.094187,"marketCap":48587347},{"date":"2024-09-27","current":-2.294503,"twenty":-6.055645,"median":-3.0882,"eighty":-1.094875,"marketCap":43646261},{"date":"2024-10-04","current":-1.933732,"twenty":-6.018828,"median":-3.074226,"eighty":-1.096448,"marketCap":36783641},{"date":"2024-10-11","current":-1.991456,"twenty":-6.007724,"median":-3.06426,"eighty":-1.097509,"marketCap":37881661},{"date":"2024-10-18","current":-2.438812,"twenty":-5.972157,"median":-3.060376,"eighty":-1.10017,"marketCap":46391309},{"date":"2024-10-25","current":-2.294503,"twenty":-5.941702,"median":-3.03122,"eighty":-1.101452,"marketCap":43646261},{"date":"2024-10-31","current":-2.381088,"twenty":-5.916977,"median":-3.023057,"eighty":-1.101452,"marketCap":45293290},{"date":"2024-11-08","current":-2.525397,"twenty":-5.911944,"median":-3.017886,"eighty":-1.101452,"marketCap":48038338},{"date":"2024-11-15","current":-2.035664,"twenty":-5.909113,"median":-3.016045,"eighty":-1.101452,"marketCap":44562371},{"date":"2024-11-22","current":-2.111059,"twenty":-5.888612,"median":-2.996328,"eighty":-1.106575,"marketCap":46212830},{"date":"2024-11-29","current":-2.65139,"twenty":-5.866126,"median":-2.988868,"eighty":-1.110673,"marketCap":58041114},{"date":"2024-12-06","current":-3.166589,"twenty":-5.85853,"median":-2.974359,"eighty":-1.111698,"marketCap":69319245},{"date":"2024-12-13","current":-2.676521,"twenty":-5.85743,"median":-2.967105,"eighty":-1.123993,"marketCap":58591266},{"date":"2024-12-20","current":-2.789614,"twenty":-5.829133,"median":-2.955503,"eighty":-1.127067,"marketCap":61066954},{"date":"2024-12-27","current":-2.638824,"twenty":-5.811316,"median":-2.943891,"eighty":-1.127067,"marketCap":57766037},{"date":"2025-01-03","current":-2.764482,"twenty":-5.804128,"median":-2.938614,"eighty":-1.127067,"marketCap":60516801},{"date":"2025-01-10","current":-2.827311,"twenty":-5.790569,"median":-2.938614,"eighty":-1.129098,"marketCap":61892183},{"date":"2025-01-17","current":-2.588561,"twenty":-5.735516,"median":-2.916584,"eighty":-1.137241,"marketCap":56665732},{"date":"2025-01-24","current":-2.575995,"twenty":-5.73225,"median":-2.915797,"eighty":-1.137313,"marketCap":56390655},{"date":"2025-01-31","current":-2.475468,"twenty":-5.73225,"median":-2.904837,"eighty":-1.137313,"marketCap":54190044},{"date":"2025-02-07","current":-2.538297,"twenty":-5.719054,"median":-2.903771,"eighty":-1.147559,"marketCap":55565426},{"date":"2025-02-14","current":-2.5006,"twenty":-5.615385,"median":-2.901813,"eighty":-1.148076,"marketCap":54740197},{"date":"2025-02-21","current":-2.236717,"twenty":-5.579497,"median":-2.888249,"eighty":-1.152623,"marketCap":48963593},{"date":"2025-02-28","current":-1.985401,"twenty":-5.541774,"median":-2.868902,"eighty":-1.165176,"marketCap":43462066},{"date":"2025-03-07","current":-2.073362,"twenty":-5.534586,"median":-2.845354,"eighty":-1.172146,"marketCap":45387601},{"date":"2025-03-14","current":-1.985401,"twenty":-5.520211,"median":-2.842004,"eighty":-1.173175,"marketCap":43462066},{"date":"2025-03-21","current":-2.286981,"twenty":-5.502241,"median":-2.829268,"eighty":-1.174313,"marketCap":50063899},{"date":"2025-03-28","current":-2.193309,"twenty":-5.498647,"median":-2.816758,"eighty":-1.178868,"marketCap":47404804},{"date":"2025-04-04","current":-2.026566,"twenty":-5.473324,"median":-2.814746,"eighty":-1.182724,"marketCap":43800930},{"date":"2025-04-11","current":-1.876497,"twenty":-5.463565,"median":-2.796559,"eighty":-1.183421,"marketCap":40557444},{"date":"2025-04-17","current":-2.01374,"twenty":-5.462708,"median":-2.786951,"eighty":-1.186495,"marketCap":43523709},{"date":"2025-04-25","current":-2.244614,"twenty":-5.451927,"median":-2.764482,"eighty":-1.190488,"marketCap":48513689},{"date":"2025-05-02","current":-2.616579,"twenty":-5.433958,"median":-2.746872,"eighty":-1.191784,"marketCap":56553100},{"date":"2025-05-09","current":-2.751256,"twenty":-5.40031,"median":-2.741859,"eighty":-1.192914,"marketCap":59463921},{"date":"2025-05-16","current":-2.77262,"twenty":-5.376785,"median":-2.741859,"eighty":-1.19591,"marketCap":57939205},{"date":"2025-05-23","current":-3.215034,"twenty":-5.372861,"median":-2.751256,"eighty":-1.198236,"marketCap":67184276},{"date":"2025-05-30","current":-3.001587,"twenty":-5.371163,"median":-2.741859,"eighty":-1.200485,"marketCap":62723909},{"date":"2025-06-06","current":-2.921545,"twenty":-5.340508,"median":-2.75157,"eighty":-1.203382,"marketCap":61051271},{"date":"2025-06-13","current":-3.321757,"twenty":-5.292213,"median":-2.764482,"eighty":-1.205807,"marketCap":69414459},{"date":"2025-06-20","current":-3.185499,"twenty":-5.277648,"median":-2.77262,"eighty":-1.209038,"marketCap":66567094},{"date":"2025-06-27","current":-2.985572,"twenty":-5.250768,"median":-2.77262,"eighty":-1.21087,"marketCap":62389243},{"date":"2025-07-03","current":-3.398754,"twenty":-5.229106,"median":-2.77918,"eighty":-1.211971,"marketCap":71023469},{"date":"2025-07-11","current":-3.615245,"twenty":-5.199968,"median":-2.789614,"eighty":-1.214159,"marketCap":75547464},{"date":"2025-07-18","current":-3.891907,"twenty":-5.183433,"median":-2.801329,"eighty":-1.214271,"marketCap":81328835},{"date":"2025-07-25","current":-3.718637,"twenty":-5.157515,"median":-2.814746,"eighty":-1.214271,"marketCap":77708031},{"date":"2025-08-01","current":-3.625338,"twenty":-5.131598,"median":-2.81579,"eighty":-1.219282,"marketCap":75758367},{"date":"2025-08-08","current":-3.185499,"twenty":-5.10332,"median":-2.827311,"eighty":-1.229528,"marketCap":66567094},{"date":"2025-08-15","current":-2.730486,"twenty":-5.097042,"median":-2.829268,"eighty":-1.234651,"marketCap":63146703},{"date":"2025-08-22","current":-2.842698,"twenty":-5.08535,"median":-2.829268,"eighty":-1.239774,"marketCap":65741773},{"date":"2025-08-29","current":-2.855166,"twenty":-5.05541,"median":-2.828289,"eighty":-1.244005,"marketCap":66030114},{"date":"2025-09-05","current":-2.730486,"twenty":-5.050611,"median":-2.822035,"eighty":-1.244719,"marketCap":63146703},{"date":"2025-09-12","current":-3.135663,"twenty":-5.041037,"median":-2.829268,"eighty":-1.248455,"marketCap":72517025},{"date":"2025-09-19","current":-2.952043,"twenty":-5.032845,"median":-2.829268,"eighty":-1.252766,"marketCap":68270533},{"date":"2025-09-26","current":-2.88142,"twenty":-5.021216,"median":-2.841134,"eighty":-1.258937,"marketCap":66637267},{"date":"2025-10-03","current":-2.966167,"twenty":-4.985765,"median":-2.842786,"eighty":-1.268463,"marketCap":68597186},{"date":"2025-10-10","current":-3.644148,"twenty":-4.976383,"median":-2.845354,"eighty":-1.279486,"marketCap":84276543},{"date":"2025-10-17","current":-3.813644,"twenty":-4.96287,"median":-2.862331,"eighty":-1.301444,"marketCap":88196382},{"date":"2025-10-24","current":-4.84474,"twenty":-4.948112,"median":-2.867634,"eighty":-1.307734,"marketCap":112042071},{"date":"2025-10-31","current":-5.18373,"twenty":-4.985765,"median":-2.87798,"eighty":-1.309486,"marketCap":119881750},{"date":"2025-11-07","current":-4.279756,"twenty":-5.021216,"median":-2.888249,"eighty":-1.309839,"marketCap":98975940},{"date":"2025-11-14","current":-5.144377,"twenty":-5.032845,"median":-2.892422,"eighty":-1.318833,"marketCap":121216121},{"date":"2025-11-21","current":-5.728642,"twenty":-5.087688,"median":-2.895544,"eighty":-1.321082,"marketCap":134983049},{"date":"2025-11-28","current":-6.0564,"twenty":-5.114631,"median":-2.902547,"eighty":-1.327626,"marketCap":142705960},{"date":"2025-12-05","current":-6.897171,"twenty":-5.157243,"median":-2.904837,"eighty":-1.332191,"marketCap":162516905},{"date":"2025-12-12","current":-10.51676,"twenty":-5.211623,"median":-2.904928,"eighty":-1.33431,"marketCap":247804702},{"date":"2025-12-19","current":-8.136951,"twenty":-5.289147,"median":-2.91247,"eighty":-1.337021,"marketCap":191729654},{"date":"2025-12-26","current":-12.836836,"twenty":-5.371163,"median":-2.916322,"eighty":-1.338637,"marketCap":302472279},{"date":"2026-01-02","current":-11.696281,"twenty":-5.41795,"median":-2.917888,"eighty":-1.340452,"marketCap":275597564},{"date":"2026-01-09","current":-11.383187,"twenty":-5.466136,"median":-2.921725,"eighty":-1.344254,"marketCap":268220191},{"date":"2026-01-16","current":-10.533362,"twenty":-5.515013,"median":-2.937918,"eighty":-1.347072,"marketCap":248195894},{"date":"2026-01-23","current":-11.741009,"twenty":-5.570525,"median":-2.938614,"eighty":-1.347358,"marketCap":276651474},{"date":"2026-01-30","current":-13.306477,"twenty":-5.728642,"median":-2.945341,"eighty":-1.34919,"marketCap":313538338},{"date":"2026-02-06","current":-13.306477,"twenty":-5.742892,"median":-2.952043,"eighty":-1.354812,"marketCap":313538338},{"date":"2026-02-13","current":-16.616323,"twenty":-5.822097,"median":-2.95297,"eighty":-1.354812,"marketCap":391527706},{"date":"2026-02-20","current":-17.466148,"twenty":-5.866126,"median":-2.95985,"eighty":-1.357046,"marketCap":411552003},{"date":"2026-02-27","current":-18.986888,"twenty":-5.914512,"median":-2.965852,"eighty":-1.364365,"marketCap":447384956},{"date":"2026-03-06","current":-19.098708,"twenty":-6.002538,"median":-2.972244,"eighty":-1.366055,"marketCap":450019732},{"date":"2026-03-13","current":-22.609828,"twenty":-6.0564,"median":-2.985572,"eighty":-1.366055,"marketCap":532751697},{"date":"2026-03-20","current":-21.648184,"twenty":-6.073669,"median":-2.988868,"eighty":-1.366055,"marketCap":510092623},{"date":"2026-03-27","current":-15.688608,"twenty":-6.133351,"median":-2.995433,"eighty":-1.368998,"marketCap":461850867},{"date":"2026-04-02","current":-15.508693,"twenty":-6.180411,"median":-3.004773,"eighty":-1.370899,"marketCap":456554412},{"date":"2026-04-10","current":-17.557481,"twenty":-6.268526,"median":-3.017886,"eighty":-1.375049,"marketCap":516867897},{"date":"2026-04-17","current":-17.935642,"twenty":-6.382533,"median":-3.020472,"eighty":-1.377298,"marketCap":528000436},{"date":"2026-04-24","current":-18.313804,"twenty":-6.484748,"median":-3.030476,"eighty":-1.380671,"marketCap":539132975},{"date":"2026-05-01","current":-16.080852,"twenty":-6.617137,"median":-3.040852,"eighty":-1.38292,"marketCap":473397981},{"date":"2026-05-08","current":-17.17932,"twenty":-6.693474,"median":-3.061413,"eighty":-1.386293,"marketCap":505735357},{"date":"2026-05-15","current":-15.305309,"twenty":-6.890735,"median":-3.06465,"eighty":-1.391914,"marketCap":535422129},{"date":"2026-05-22","current":-17.296646,"twenty":-7.097254,"median":-3.073723,"eighty":-1.400909,"marketCap":605084640},{"date":"2026-05-29","current":-17.635796,"twenty":-7.263784,"median":-3.075922,"eighty":-1.407051,"marketCap":616949045},{"date":"2026-06-05","current":-16.797897,"twenty":-7.436317,"median":-3.090521,"eighty":-1.410123,"marketCap":587636986},{"date":"2026-06-12","current":-16.159497,"twenty":-7.738114,"median":-3.093289,"eighty":-1.412152,"marketCap":565303989},{"date":"2026-06-18","current":-18.579553,"twenty":-7.918223,"median":-3.10494,"eighty":-1.414041,"marketCap":649964252},{"date":"2026-06-26","current":-19.780203,"twenty":-8.159674,"median":-3.111001,"eighty":-1.415211,"marketCap":691966323},{"date":"2026-07-02","current":-20.004053,"twenty":-8.516704,"median":-3.118844,"eighty":-1.416649,"marketCap":699797218},{"date":"2026-07-10","current":-22.568153,"twenty":-8.769676,"median":-3.121651,"eighty":-1.416649,"marketCap":789496556},{"date":"2026-07-17","current":-20.472103,"twenty":-9.289673,"median":-3.131839,"eighty":-1.422271,"marketCap":716170907},{"date":"2026-07-24","current":-17.908002,"twenty":-9.430212,"median":-3.133958,"eighty":-1.427893,"marketCap":626471568},{"date":"2026-07-31","current":-17.399252,"twenty":-9.8224,"median":-3.141277,"eighty":-1.430474,"marketCap":608674081},{"date":"2026-08-07","current":-20.472103,"twenty":-10.105532,"median":-3.158168,"eighty":-1.437533,"marketCap":716170907},{"date":"2026-08-14","current":-19.570739,"twenty":-10.293284,"median":-3.161751,"eighty":-1.457125,"marketCap":781209308},{"date":"2026-08-21","current":-23.585249,"twenty":-10.488192,"median":-3.163444,"eighty":-1.461622,"marketCap":941457372},{"date":"2026-08-28","current":-25.64627,"twenty":-10.896063,"median":-3.168385,"eighty":-1.468573,"marketCap":1023727583},{"date":"2026-09-04","current":-24.786018,"twenty":-11.124943,"median":-3.175054,"eighty":-1.471693,"marketCap":989388712},{"date":"2026-09-11","current":-22.760841,"twenty":-11.372411,"median":-3.185499,"eighty":-1.475907,"marketCap":908549287},{"date":"2026-09-16","current":-21.757213,"twenty":-11.593976,"median":-3.189215,"eighty":-1.479611,"marketCap":868487271}],"updateTime":1789706781821},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMMX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637814503","title":"Immix Biopharma Announces 95% Complete Response Rate in Interim Update From Relapsed/Refractory Al Amyloidosis Clinical Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2637814503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637814503?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA6B5BBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637384847","title":"Immix Biopharma, Inc: Next Nexicart-2 Update Expected Late September, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637384847","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637384847?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA6B5BBV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381096","title":"Immix Biopharma Inc - Plans to Initiate Phase 3 Trial in Newly Diagnosed Al Amyloidosis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637381096?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA6B5BBV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138487","title":"Immix Biopharma: by March End 2027, Expect to Present 1-Year Follow-up Data of Enrolled Patients; Sees It to Drive Bla Submission, Commercial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637138487?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA6B5BBV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635072776","title":"Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635072776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635072776?lang=en_us&edition=fundamental","pubTime":"2026-05-15 11:18","pubTimestamp":1778815119,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T program for relapsed or refractory AL amyloidosis, a setting it estimates at about 38,500 U.S. patients with no FDA-approved therapies.Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201, versus 0%-10% complete response rates cited for investigator’s-choice regimens used off label in this population.Presentation outlined a registrational-design NEXICART-2 U.S. trial, with a planned topline readout in Q3 2026.Commercial planning targets launch in 1H 2027, with buildout focused on high-prescribing treatment sites.Market framing assumed existing reimbursement benchmarks for BCMA CAR-T at about $422,000 per patient, positioning opportunity as multi-billion-dollar scale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4wVG0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635816157","title":"3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635816157","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635816157?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:05","pubTimestamp":1778670334,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and potential for substantial earnings expansion.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-ofrm/once-upon-a-farm-pbc/news/3-growth-companies-with-high-insider-ownership-expect-earnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-ofrm/once-upon-a-farm-pbc/news/3-growth-companies-with-high-insider-ownership-expect-earnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2087625088.SGD","LU2931357623.SGD","LU0274383776.USD","BK4212","OFRM","BK4563","LU2290526834.HKD","IE00BZ9MQY76.HKD","LU1852331112.SGD","APPX","BK4516","LU0097036916.USD","LU2360107168.USD","IMMX","BK4505","LU0056508442.USD","IE00B19Z9P08.USD","BK4122","LU2089985449.USD","RUM","BK4023","IE00B894F039.SGD","BK4009","BK4006","BK4608","BK4214","BK4561","LU2250418816.HKD","LU2063271972.USD","BK4141","UPSX","LU2360106780.USD","BK4139","BK4588","LU0353189680.USD","LU1861215975.USD","BK4166","BK4187","LU1861220033.SGD","LU0353189763.USD","BK4539","LABX","BK4082","BK4135","BK4613","IE00B19Z9Z06.USD","BK4077","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635229646","title":"Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635229646","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635229646?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:21","pubTimestamp":1778628087,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T being developed for relapsed or refractory AL amyloidosis, a setting it estimates at about 38,500 U.S. patients with no FDA-approved drugs.Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201, versus 0-10% complete response cited for current investigator’s-choice regimens in relapsed or refractory disease.Company outlined a registrational design for U.S. NEXICART-2, with final readout targeted for topline in Q3, followed by a planned BLA submission.Commercial timeline calls for launch planning in late 2026, with a commercial launch plan in 1H 2027.Presentation also framed NXC-201 as a platform candidate beyond AL amyloidosis, targeting plasma cells across selected immune-mediated diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7Yt8JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633310508","title":"Immix Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633310508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633310508?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:19","pubTimestamp":1778195953,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc reports results for the quarter ended March 31 - Earnings SummaryImmix Biopharma Inc IMMX.OQ reported a quarterly adjusted loss of 18 cents per share for the quarter ended March 31","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633103993","title":"Immix Biopharma Q1 net loss widens to USD 10.09 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633103993","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633103993?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:20","pubTimestamp":1778192428,"startTime":"0","endTime":"0","summary":"Immix Biopharma posted a net loss of USD 10.09 million for the quarter ended March 31, 2026, widening from USD 4.54 million a year earlier.Research and development expense climbed to USD 5.98 million from USD 1.98 million, while general and administrative costs rose to USD 4.82 million from USD 2.71 million.Interest income increased to USD 717,168 from USD 150,219, reflecting interest on money market funds and US Treasuries.Cash, cash equivalents, and short-term investments totaled about USD 90.6 million at March 31, 2026; total assets were about USD 95.8 million with working capital of about USD 81.7 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL6thqzg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633961673","title":"Immix Biopharma Inc  expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961673","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961673?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:14","pubTimestamp":1777929261,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of21cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to  report resultson May 6 (estimated) for the period ending March 31 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H2EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633950636","title":"Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633950636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633950636?lang=en_us&edition=fundamental","pubTime":"2026-05-05 02:15","pubTimestamp":1777918512,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted clinical data for BCMA-targeted CAR-T NXC-201 in relapsed or refractory AL amyloidosis.ASH 2025 dataset cited 75% complete response rate for NXC-201, versus 0-10% complete response rate cited for current investigator’s choice regimens in this setting.U.S. relapsed or refractory AL amyloidosis population estimated at about 38,500 patients, with no FDA-approved therapies cited for this segment.Commercial planning cited launch in 1H 2027, supported by 20 high-prescribing sites in existing clinical trial network.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL3V56kV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632883139","title":"Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2632883139","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632883139?lang=en_us&edition=fundamental","pubTime":"2026-05-03 23:36","pubTimestamp":1777822594,"startTime":"0","endTime":"0","summary":"Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T program positioned for relapsed or refractory AL amyloidosis, where it estimates about 38,500 patients in US lack an FDA-approved treatment option.Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201 in relapsed or refractory AL amyloidosis, versus 0%-10% complete response rates cited for current investigator’s-choice regimens.Reimbursement benchmark for BCMA CAR-T was cited at about $422,000, framing a multi-billion-dollar commercial opportunity based on the estimated patient pool.Development timeline pointed to NXC-201 NEXICART-2 as a US trial with registrational design, with final readout targeted for a Q3 topline and a commercial launch plan in 1H 2027.Presentation also outlined potential expansion into immune-mediated diseases beyond AL amyloidosis, with neurology and rheumatology among highlighted areas.Disclaimer: This news brief was created by Public Technologies  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260503:nNDL64kkGj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626739182","title":"Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2626739182","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626739182?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:45","pubTimestamp":1775738735,"startTime":"0","endTime":"0","summary":"Immix Biopharma will participate in Jefferies Global Healthcare Conference June 2-4, 2026 in New York.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL3sCP2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014013.SGD","IMMX","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","BK4588","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625860127","title":"Immix Biopharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625860127","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625860127?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:38","pubTimestamp":1775507928,"startTime":"0","endTime":"0","summary":"Immix Biopharma scheduled annual shareholder meeting in Los Angeles on May 22, 2026.Shareholders will vote to elect nine directors to serve until next annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL846Dx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623898765","title":"Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623898765","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623898765?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:05","pubTimestamp":1774958720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1EC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","LU1699723380.USD","LU0868494617.USD","LU1116320901.HKD","BK4516","LU2324357040.USD","LU2361044949.HKD","SG9999015341.SGD","LU1989772923.USD","SGXZ57979304.SGD","LU1929549753.HKD","BK4559","LU2023250504.SGD","SG9999014542.SGD","LU0648001328.SGD","IE00B4R5TH58.HKD","LU1066051498.USD","LU1941712348.USD","LU1934455863.HKD","LU2023250843.SGD","LU0965509101.SGD","LU1989771016.USD","LU0265550946.USD","BK4007","LU2361045086.USD","LU0868494708.USD","LU1035773651.USD","LU0965508806.USD","LU0208291251.USD","LU1917777945.USD","LU1037948541.HKD","LU2461242641.AUD","LU1934455194.USD","IE00B1BXHZ80.USD","LU0106261372.USD","LU1934455277.USD","SG9999001440.SGD","LU0861579265.USD","LU1941712264.USD","LU0965509010.AUD","LU0289739699.SGD","LU1061106388.HKD","LU1571399168.USD","SG9999001176.SGD","IE00BSNM7G36.USD","LU2360032135.SGD","LU0203347892.USD","LU2361044865.SGD","LU0980610538.SGD","BK4533","LU1066053197.SGD","SG9999002232.USD","LU1983299246.USD","IE0002141913.USD","LU1116320737.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU2106854487.HKD","LU0238689110.USD","IE00BLSP4239.USD","LU0477156953.USD","LU0266013472.USD","SG9999015358.SGD","LU0211331839.USD","LU1066051811.HKD","LU1057294990.SGD","SG9999014567.USD","LU1585245621.USD","LU1066051225.USD","LU0965509283.SGD","LU1974910355.USD","LU1162221912.USD","SG9999014559.SGD","LU1430594728.SGD","LU0098860793.USD","LU1989772840.SGD","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU0122379950.USD","LU0942090050.USD","LU0234572021.USD","BK4588","LU2125154935.USD","LU1291159041.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","SG9999013999.USD","SG9999001176.USD","IE00BN8TJ469.HKD","LU1093756168.USD","LU1023059063.AUD","LU2089984988.USD","LU0058720904.USD","MRK","LU2112291526.USD","LU1037948897.HKD","LU0130102774.USD","LU0265550359.USD","LU0432979614.USD","IE00BJT1NW94.SGD","BK4585","LU1201861249.SGD","IE00BJJMRZ35.SGD","LU0006306889.USD","IE0009355771.USD","IMMX","LU0320765646.SGD","LU2125154778.USD","LU0130517989.USD","BK4534","LU1093756325.SGD","LU0320765489.SGD","LU2468319806.SGD","IE00B2B36J28.USD","LU1069347547.HKD","SG9999014575.USD","LU0985320562.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328908","title":"Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328908","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623328908?lang=en_us&edition=fundamental","pubTime":"2026-03-31 01:43","pubTimestamp":1774892580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 13:43 ET (17:43 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623459893","title":"Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon","url":"https://stock-news.laohu8.com/highlight/detail?id=2623459893","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623459893?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:38","pubTimestamp":1774877922,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-completes-nexicart-2-enrollment-onboards-cmo-richard-graydon-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-completes-nexicart-2-enrollment-onboards-cmo-richard-graydon-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310705","title":"Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310705","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310705?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874730,"startTime":"0","endTime":"0","summary":"Immix Biopharma completed enrollment in NEXICART-2, its BLA-enabling trial in relapsed or refractory AL amyloidosis.Positive interim data were previously presented at ASH 2025.Topline NEXICART-2 results are expected in Q3 2026.BLA submission is planned following topline results, with commercial launch planned thereafter.Richard Graydon joined as chief medical officer to support BLA submission.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8f0s4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2095319765.USD","IE00BN0W2T93.GBP","BK4112","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","IE00B3QW5Z07.USD","IMMX","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623310711","title":"Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2623310711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623310711?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:45","pubTimestamp":1774874700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA7FGJWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823988","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823988","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823988?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:08","pubTimestamp":1774609680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 07:08 ET (11:08 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":70,"code":"91000000","status":"200"}]}}